An Act amending the act of November 3, 2022 (P.L.2135, No.150), known as the Childhood Blood Lead Test Act, further providing for legislative purpose, for definitions, for lead poisoning prevention, assessment and testing and for blood lead assessment and testing coverage.

SB 850 amends Pennsylvania's Childhood Blood Lead Test Act to require all children under 72 months to receive at least one blood lead test by age 2 (or by 72 months if never tested), and mandates confirmatory testing if initial results indicate elevated lead levels. It directly affects children under 72 months and pregnant women, ensuring no out-of-pocket costs (like copays or deductibles) for covered blood lead tests. The bill updates testing requirements to be mandatory (replacing "encourage" with "require") and clarifies that health insurance must cover these tests without cost-sharing. These changes aim to improve early detection of lead exposure, a preventable health risk linked to developmental issues in young children.